Pharsight

1. List of Aemcolo drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8263120	REDHILL	Oral antimicrobial pharmaceutical compositions	May, 2025 (1 year, 11 months from now)
US8486446	REDHILL	Oral antimicrobial pharmaceutical compositions	May, 2025 (1 year, 11 months from now)
US8741948	REDHILL	Oral antimicrobial pharmaceutical compositions	May, 2025 (1 year, 11 months from now)
US8529945	REDHILL	Oral antimicrobial pharmaceutical compositions	May, 2025 (1 year, 11 months from now)

Do you want to check out AEMCOLO patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Nov 16, 2023
Generating Antibiotic Incentives Now (GAIN)	Nov 16, 2028

Drugs and Companies using RIFAMYCIN SODIUM ingredient

NCE-1 date: 2027-11-17

Market Authorisation Date: 16 November, 2018

Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults

Dosage: TABLET, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 194MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription

AEMCOLO family patents

United States

European Union

China

Canada

Japan

Korea, Republic of

Italy

Spain

Austria

Denmark

Germany

Poland

Croatia

Cyprus

Portugal

Mexico

South Africa

Slovenia

Hungary

2. List of Brenzavvy drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8802637	THERACOSBIO	Benzylbenzene derivatives and methods of use	Aug, 2028 (5 years from now)
US7838499	THERACOSBIO	Benzylbenzene derivatives and methods of use	Jan, 2029 (5 years from now)
US10981942	THERACOSBIO	Crystalline form of benzylbenzene SGLT2 inhibitor	Jun, 2031 (8 years from now)
US8987323	THERACOSBIO	Crystalline form of benzylbenzene SGLT2 inhibitor	May, 2032 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8106021	THERACOSBIO	Benzylbenzene derivatives and methods of use	Aug, 2028 (5 years from now)
US10533032	THERACOSBIO	Crystalline form of benzylbenzene SGLT2 inhibitor	Jul, 2031 (8 years from now)

Do you want to check out BRENZAVVY patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 20, 2028

Drugs and Companies using BEXAGLIFLOZIN ingredient

NCE-1 date: 2027-01-20

Market Authorisation Date: 20 January, 2023

Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes

Dosage: TABLET;ORAL

Strength	Dosage	Availability
20MG	TABLET;ORAL	Prescription

3. List of Daybue drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US11370755	ACADIA PHARMS INC	Compositions of trofinetide	Aug, 2040 (17 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9212204	ACADIA PHARMS INC	Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid	Jan, 2032 (8 years from now)

Do you want to check out DAYBUE patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 10, 2030
New Chemical Entity Exclusivity (NCE)	Mar 10, 2028

Drugs and Companies using TROFINETIDE ingredient

NCE-1 date: 2027-03-11

Market Authorisation Date: 10 March, 2023

Treatment: Treatment of rett syndrome or a symptom thereof

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
200MG/ML	SOLUTION;ORAL	Prescription

4. List of Filspari drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9993461	TRAVERE	Method for treating disorders associated with glomerular function	Mar, 2030 (6 years from now)

Do you want to check out FILSPARI patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Feb 17, 2030
New Chemical Entity Exclusivity (NCE)	Feb 17, 2028

Drugs and Companies using SPARSENTAN ingredient

NCE-1 date: 2027-02-17

Market Authorisation Date: 17 February, 2023

Treatment: Treatment of primary immunoglobulin a nephropathy (igan) in adults at risk of rapid disease progression

Dosage: TABLET;ORAL

Strength	Dosage	Availability
200MG	TABLET;ORAL	Prescription
400MG	TABLET;ORAL	Prescription

5. List of Jaypirca drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10695323	LOXO ONCOL	Compounds useful as kinase inhibitors	Dec, 2036 (13 years from now)
US10342780	LOXO ONCOL	Compounds useful as kinase inhibitors	Dec, 2036 (13 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10464905	LOXO ONCOL	Compounds useful as kinase inhibitors	Dec, 2036 (13 years from now)
US10918622	LOXO ONCOL	Compounds useful as kinase inhibitors	Dec, 2036 (13 years from now)

Do you want to check out JAYPIRCA patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Jan 27, 2030
New Chemical Entity Exclusivity (NCE)	Jan 27, 2028

Drugs and Companies using PIRTOBRUTINIB ingredient

NCE-1 date: 2027-01-27

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after at least two lines of systemic therapy, including a btk inhibitor

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription

6. List of Jesduvroq drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8324208	GLAXOSMITHKLINE	Prolyl hydroxylase inhibitors	Dec, 2028 (5 years from now)
US11117871	GLAXOSMITHKLINE	Crystalline forms of GSK1278863, preparation method and pharmaceutical use thereof	Mar, 2038 (14 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8557834	GLAXOSMITHKLINE	Prolyl hydroxylase inhibitors	Jun, 2027 (4 years from now)
US8815884	GLAXOSMITHKLINE	Prolyl hydroxylase inhibitors	Jun, 2027 (4 years from now)

Do you want to check out JESDUVROQ patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Feb 1, 2028

Drugs and Companies using DAPRODUSTAT ingredient

NCE-1 date: 2027-02-01

Market Authorisation Date: 01 February, 2023

Treatment: Treatment of anemia due to chronic kidney disease; A method of treating anemia

Dosage: TABLET;ORAL

Strength	Dosage	Availability
1MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription
4MG	TABLET;ORAL	Prescription
6MG	TABLET;ORAL	Prescription
8MG	TABLET;ORAL	Prescription

7. List of Joenja drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8653092	PHARMING	Tetrahydro-pyrido-pyrimidine derivatives	Feb, 2032 (8 years from now)

Do you want to check out JOENJA patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Mar 24, 2030
New Chemical Entity Exclusivity (NCE)	Mar 24, 2028

Drugs and Companies using LENIOLISIB PHOSPHATE ingredient

NCE-1 date: 2027-03-25

Market Authorisation Date: 24 March, 2023

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 70MG BASE	TABLET;ORAL	Prescription

8. List of Nuzyra drug patents

Application	Filing Date	Opposition Party	Legal Status
EP18158017A	2021-05-28	Lederer & Keller Patentanwälte Partnerschaft mbB	Granted and Under Opposition

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7326696	PARATEK PHARMS INC	Amino-methyl substituted tetracycline compounds	Sep, 2023 (3 months from now)
US7553828	PARATEK PHARMS INC	9-aminomethyl substituted minocycline compounds	Jun, 2024 (1 year, 3 days from now)
US8383610	PARATEK PHARMS INC	Salts and polymorphs of 9-(2,2-dimethylpropyl-aminomethyl) minocycline	Sep, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9265740	PARATEK PHARMS INC	Minocycline compounds and methods of use thereof	Mar, 2029 (5 years from now)
US10124014	PARATEK PHARMS INC	Minocycline compounds and methods of use thereof	Mar, 2029 (5 years from now)
US9724358	PARATEK PHARMS INC	Minocycline compounds and methods of use thereof	Mar, 2029 (5 years from now)
US9314475	PARATEK PHARMS INC	Oral and injectable formulations of tetracycline compounds	Mar, 2031 (7 years from now)
US10111890	PARATEK PHARMS INC	9-aminomethyl minocycline compounds and uses thereof	Aug, 2037 (14 years from now)
US10835542	PARATEK PHARMS INC	9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)	Oct, 2037 (14 years from now)
US10383884	PARATEK PHARMS INC	9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)	Oct, 2037 (14 years from now)

Do you want to check out NUZYRA patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Oct 2, 2023
Generating Antibiotic Incentives Now (GAIN)	Oct 2, 2028

Drugs and Companies using OMADACYCLINE TOSYLATE ingredient

NCE-1 date: 2027-10-03

Market Authorisation Date: 02 October, 2018

Treatment: Treatment of bacterial skin and skin structure infection; Treatment of bacterial skin and skin structure infections; Treatment of subjects having bacterial skin or skin structure infection; Treatment ...

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 150MG BASE	TABLET;ORAL	Prescription

NUZYRA family patents

United States

Japan

European Union

China

Australia

Korea, Republic of

Canada

Taiwan

Brazil

Spain

Denmark

Croatia

Mexico

Russia

Portugal

Slovenia

Poland

Singapore

South Africa

Hungary

Hong Kong

New Zealand

Cyprus

Lithuania

Austria

Philippines

Czech Republic

Morocco

Argentina

Israel

Chile

Ecuador

Colombia

Tunisia

Malaysia

Turkey

Germany

Ukraine

Norway

9. List of Orserdu drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8399520	STEMLINE THERAP	Selective estrogen receptor modulator	Dec, 2023 (6 months from now)
US7612114	STEMLINE THERAP	Selective estrogen receptor modulator	Aug, 2026 (3 years from now)
US10385008	STEMLINE THERAP	Polymorphic forms of RAD1901-2HCL	Jan, 2038 (14 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071066	STEMLINE THERAP	Method of treating cancer using selective estrogen receptor modulators	Oct, 2034 (11 years from now)
US10420734	STEMLINE THERAP	Method of treating cancer using selective estrogen receptor modulators	Oct, 2034 (11 years from now)
US10745343	STEMLINE THERAP	Polymorphic forms of RAD1901-2HCl	Jan, 2038 (14 years from now)

Do you want to check out ORSERDU patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 27, 2028

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-01-27

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of an er-positive breast cancer following at least one line of endocrine therapy; Treatment of an er-positive breast cancer

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 86MG BASE	TABLET;ORAL	Prescription
EQ 345MG BASE	TABLET;ORAL	Prescription

10. List of Skyclarys drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9670147	REATA PHARMS	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17	Apr, 2029 (5 years from now)
US8124799	REATA PHARMS	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at C-17	Dec, 2029 (6 years from now)
US8993640	REATA PHARMS	2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	Apr, 2033 (9 years from now)
US9701709	REATA PHARMS	2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof	Apr, 2033 (9 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8440854	REATA PHARMS	Antioxidant inflammation modulators: oleanolic acid derivatives with amino acid and other modifications at C-17	Apr, 2029 (5 years from now)
US11091430	REATA PHARMS	Antioxidant inflammation modulators: oleanolic acid derivatives with amino and other modifications at c-17	Apr, 2029 (5 years from now)

Do you want to check out SKYCLARYS patents from before 2022?

Exclusivity	Exclusivity Expiration
Orphan Drug Exclusivity (ODE)	Feb 28, 2030
New Chemical Entity Exclusivity (NCE)	Feb 28, 2028

Drugs and Companies using OMAVELOXOLONE ingredient

NCE-1 date: 2027-02-28

Market Authorisation Date: 28 February, 2023

Treatment: Treatment of friedreich's ataxia in adults and adolescents aged 16 years and older

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
50MG	CAPSULE;ORAL	Prescription

11. List of Xerava drug patents

Application	Filing Date	Opposition Party	Legal Status
EP15180611A	2018-07-18	Sandoz AG	Revoked

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10961190	TETRAPHASE PHARMS	Crystalline forms of eravacycline	Oct, 2037 (14 years from now)
US11578044	TETRAPHASE PHARMS	Crystalline forms of eravacycline	Oct, 2037 (14 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8796245	TETRAPHASE PHARMS	C7-fluoro substituted tetracycline compounds	Aug, 2029 (6 years from now)
US8906887	TETRAPHASE PHARMS	C7-fluoro substituted tetracycline compounds	Dec, 2030 (7 years from now)

Do you want to check out XERAVA patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Aug 27, 2023
Generating Antibiotic Incentives Now (GAIN)	Aug 27, 2028

Drugs and Companies using ERAVACYCLINE DIHYDROCHLORIDE ingredient

NCE-1 date: 2027-08-28

Market Authorisation Date: 27 August, 2018

Treatment: Treatment of complicated intra-abdominal infections in patients 18 years of age and older

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 50MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription
EQ 100MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

XERAVA family patents

United States

Japan

China

Korea, Republic of

European Union

Spain

Hong Kong

Poland

Argentina

New Zealand

Israel

Taiwan

Denmark

Singapore

Croatia

Cyprus

Portugal

Mexico

Slovenia

Hungary

Philippines

Brazil

Canada

Morocco

Norway

San Marino

Australia

Netherlands

Colombia

Lithuania

Luxembourg

12. List of Zavzpret drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7220862	PFIZER	Calcitonin gene related peptide receptor antagonists	Jan, 2024 (7 months from now)
US8481546	PFIZER	CGRP receptor antagonist	Oct, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7314883	PFIZER	Anti-migraine treatments	Dec, 2023 (6 months from now)

Do you want to check out ZAVZPRET patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Mar 9, 2028

Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient

NCE-1 date: 2027-03-10

Market Authorisation Date: 09 March, 2023

Treatment: Administration of zavegepant for acute treatment of migraine with or without aura

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
EQ 10MG BASE/SPRAY	SPRAY, METERED;NASAL	Prescription

13. List of Zemdri drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9688711	CIPLA USA	Antibacterial aminoglycoside analogs	Nov, 2028 (5 years from now)
US8383596	CIPLA USA	Antibacterial aminoglycoside analogs	Jun, 2031 (8 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8822424	CIPLA USA	Antibacterial aminoglycoside analogs	Nov, 2028 (5 years from now)
US9266919	CIPLA USA	Antibacterial aminoglycoside analogs	Nov, 2028 (5 years from now)

Do you want to check out ZEMDRI patents from before 2022?

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jun 25, 2023
Generating Antibiotic Incentives Now (GAIN)	Jun 25, 2028

Drugs and Companies using PLAZOMICIN SULFATE ingredient

NCE-1 date: 2027-06-26

Market Authorisation Date: 25 June, 2018

Treatment: Method of using plazomicin to treat bacterial infections

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 500MG BASE/10ML (EQ 50MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription

ZEMDRI family patents

United States

China

Japan

European Union

Spain

Denmark

Poland

Brazil

Canada

Croatia

Korea, Republic of

Cyprus

Israel

Portugal

Taiwan

Mexico

Australia

Lithuania

Slovenia

Hungary

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in

Drugs expiring in 2028

Drugs that contains Dasatinib

Pharsight

Drugs facing NCE-1 in 2027

1. List of Aemcolo drug patents

AEMCOLO family patents

2. List of Brenzavvy drug patents

3. List of Daybue drug patents

4. List of Filspari drug patents

5. List of Jaypirca drug patents

6. List of Jesduvroq drug patents

7. List of Joenja drug patents

8. List of Nuzyra drug patents

NUZYRA family patents

9. List of Orserdu drug patents

10. List of Skyclarys drug patents

11. List of Xerava drug patents

XERAVA family patents

12. List of Zavzpret drug patents

13. List of Zemdri drug patents

ZEMDRI family patents

Other things you might be interested in